While more research is needed, our data suggest that FDFT1 is a novel immunomodulator, and validates the power of 3D chromatin-based autoimmune variant-to-gene mapping strategies for identifying therapeutic targets for immune disease. Here, FDFT1 is linked to immune system disorder.